Keywords: ACSL4; acyl-CoA synthetase long-chain family member 4; AD; Alzheimer's disease; ARE; antioxidant-responsive element; ANT; adenine nucleotide translocase; AP-1; activator protein-1; ATP; adenosine triphosphate; Bak; Bcl-2 antagonist/killer; BCEC; brain c
مقالات ISI (ترجمه نشده)
مقالات زیر هنوز به فارسی ترجمه نشده اند.
در صورتی که به ترجمه آماده هر یک از مقالات زیر نیاز داشته باشید، می توانید سفارش دهید تا مترجمان با تجربه این مجموعه در اسرع وقت آن را برای شما ترجمه نمایند.
در صورتی که به ترجمه آماده هر یک از مقالات زیر نیاز داشته باشید، می توانید سفارش دهید تا مترجمان با تجربه این مجموعه در اسرع وقت آن را برای شما ترجمه نمایند.
Keywords: Iron chelating therapy; Deferasirox; Reactive oxygen species (ROS); MTT assay; Apoptosis; Confocal laser scanning microscope
Keywords: Rhinocerebral mucormycosis; Mucorales; Rhizopus arrhizus; Liposomal amphotericin B (AmBisome); Posaconazole; Deferasirox
Keywords: Iron overload cardiomyopathy; Iron chelator; Deferoxamine; Deferiprone; Deferasirox; Antioxidant;
Keywords: MDS; Myelodysplastic syndrome; Iron chelation; Iron overload; Transfusion-dependent; Deferasirox; Deferoxamine; Deferiprone
Keywords: Thalassemia major; Sickle cell disease; Iron overload; Iron chelation; Deferoxamine; Deferiprone; Deferasirox;
Keywords: Iron overload; Thalassemia; Sickle cell disease; Deferoxamine; Deferiprone; Deferasirox; Surcharge en fer; Thalassémie; Drépanocytose; Deferoxamine; Deferiprone; Deferasirox;
Keywords: Thalassemia; Deferasirox; Disorders of calcium; Hypercalciuria; Iron overload
Keywords: DMSA; DMPS; Deferiprone; Deferasirox; Deferoxamine
From small deferiprone to macromolecular micelles: Self-assembly enhances iron chelation
Keywords: BLG; l-glutamic acid-5-benzyl ester; CMC; critical micelle concentrations; DCC; N,Nâ²-dicyclohexylcarbodiimide; DFP; deferiprone; DFO; desferoxamine; DFX; deferasirox; DMF; N-dimethylformamide; mPEG-PGlu; poly(ethylene glycol)-poly(glutamic acid); NCA; N
A simple LC-MS/MS method for determination of deferasirox in human plasma: Troubleshooting of interference from ferric ion in method development and its application
Keywords: Deferasirox; LC-MS/MS; Pharmacokinetics; Edta;
Bone disease in β thalassemia patients: past, present and future perspectives
Keywords: AL; aledronate; BMD; bone mineral density; bw; body weight; BMD-L; lumbar spine bone mineral density; Ca; calcium supplementation; CLO; clodronate; COLIA1; collagen type I A1; D; vitamin D; DEXA; dual energy X-ray absorptiometry; DFO; desferrioxamine; DFP
To chelate or not to chelate in MDS: That is the question!
Keywords: Myelodysplastic syndromes; Transfusion; Iron chelation; Deferasirox; Deferoxamine; Deferiprone;
Solubility and thermodynamic functions of deferasirox in different solvents
Keywords: Deferasirox; Solubility; Thermodynamic functions; Apelblat equation;
Thermodynamic investigation on acid-base equilibria of deferiprone and deferasirox at different ionic strengths and various temperatures
Keywords: Deferiprone; Deferasirox; Protonation constant; Ionic strength; Temperature; Thermodynamic functions;
Changes in transferrin gene expression after exposure to iron and Aeromonas hydrophila infection in yellow snapper (Lutjanus argentiventris)
Keywords: DFX; Deferasirox; Fe2x; iron overload; LaTf; Lutjanus argentiventris transferrin; NUP; Nested Universal Primer A; OD; optical density; PCR; polymerase chain reaction; qRT-PCR; quantitative real-time RT-PCR; RACE; rapid amplification of cDNA ends; Tf; tran
A combination of an iron chelator with an antioxidant effectively diminishes the dendritic loss, tau-hyperphosphorylation, amyloids-β accumulation and brain mitochondrial dynamic disruption in rats with chronic iron-overload
Keywords: AD; Alzheimer's disease; APP; amyloid precursor protein; Aβ; amyloid-β; BBB; blood-brain barrier; DFO; deferoxamine; DFP; deferiprone; DFX; deferasirox; Drp1; dynamin-related protein 1; HFe; high-iron diet; Mfn2; mitofusin2; NAC; n-acetyl cysteine;
Proximal muscular atrophy and weakness: An unusual adverse effect of deferasirox iron chelation therapy
Keywords: Beta-thalassemia major; Iron chelation therapy; Adverse effects; Muscular weakness; Deferasirox;
Determination of deferasirox in human plasma by short-end injection and sweeping with a field-amplified sample stacking and micellar electrokinetic chromatography
Keywords: BGE; background electrolyte; CE; capillary electrophoresis; DFX; deferasirox; EOF; electroosmotic flow; FASS; field-amplified sample stacking; HPLC; high-performance liquid chromatography; LOD; limit of detection; LOQ; limit of quantitation; MEKC; micella
Development of a biphasic dissolution test for Deferasirox dispersible tablets and its application in establishing an in vitro-in vivo correlation
Keywords: Deferasirox; In vitro/in vivo correlations; Flow-through apparatus; Paddle apparatus; Biphasic dissolution medium;
Effect of deferasirox on iron overload in patients with transfusion-dependent haemoglobinopathies
Keywords: Transfusion-dependent; Haemoglobinopathies; Deferasirox; Iron overload
Updated recommendations on the management of gastrointestinal disturbances during iron chelation therapy with Deferasirox in transfusion dependent patients with myelodysplastic syndrome – Emphasis on optimized dosing schedules and new formulations
Keywords: Myelodysplastic syndrome; Transfusion; Iron overload; Chelation; Gastrointestinal disturbances; Deferasirox
Simultaneous Rp-HPLC determination of salicylamide, salicylic acid and deferasirox in the bulk API dosages forms
Keywords: Rp-HPLC; Simultaneous determination; Salicylamide; Salicylic acid; Deferasirox
Simultaneous Determination of Plasma Deferasirox and Deferasirox-Iron Complex Using an HPLC-UV System and Pharmacokinetics of Deferasirox in Patients With β-Thalassemia Major: Once-daily Versus Twice-daily Administration
Keywords: deferasirox; deferasirox-iron complex; dosing schedule; HPLC-UV; pharmacokinetics;
Deferasirox-induced cytogenetic responses
Keywords: Deferasirox; Iron chelator; Genotoxicity; Cytotoxicity; In vitro; In vivo;
Combination of deferasirox and deferoxamine in clinical practice: An alternative scheme of chelation in thalassemia major patients
Keywords: Thalassemia major; Cardiac iron overload; Deferasirox; Deferoxamine; Chelation therapy
Iron chelators induce autophagic cell death in multiple myeloma cells
Keywords: Iron chelation; Deferasirox; Deferoxamine; Multiple myeloma; Autophagy; mTOR; p70S6 kinase
Combined chelation therapy with deferasirox and deferoxamine in thalassemia
Keywords: Thalassemia major; Iron overload; Deferoxamine; Deferasirox
The oral iron chelator deferasirox might improve survival in allogeneic hematopoietic cell transplant (alloHSCT) recipients with transfusional iron overload
Keywords: Allogeneic haematopoietic stem cell transplantation; Deferasirox; Iron overload; Survival
Hierro e infección fúngica invasiva
Keywords: Mucormicosis; Aspergilosis; Quelantes del hierro; Deferoxamina; Deferasirox; Deferiprona; Mucormycosis; Aspergillosis; Iron chelators; Deferoxamine; Deferasirox; Deferiprone;
A pharmaco-economic evaluation of deferasirox for treating patients with iron overload caused by transfusion-dependent thalassemia in Taiwan
Keywords: cost–utility; deferasirox; quality-adjusted life year; thalassemia; transfusion-dependent
When is iron overload deleterious, and when and how should iron chelation therapy be administered in myelodysplastic syndromes?
Keywords: iron; red blood cell transfusion [complications]; haemosiderosis; myelodysplastic syndromes; chelation therapy; deferasirox; deferoxamine; deferiprone
Surcharge en fer d'origine hématologique
Keywords: Surcharge en fer; Transfusion; Hémochromatose; Imagerie par résonance magnétique nucléaire; Chélation; Déférasirox; Défériprone; Post-transfusional iron overload; Transfusion; Iron loading anemia; Deferasirox; Deferiprone;
Iron mobilization using chelation and phlebotomy
Keywords: Iron overload disorders; Haemochromatosis; Thalassaemia; Chelation; Deferiprone (L1); Deferoxamine (DFOA); Deferasirox
Hydrophilic interaction liquid chromatography/positive ion electrospray mass spectrometry for the quantification of deferasirox, an oral iron chelator, in human plasma
Keywords: Hydrophilic interaction liquid chromatography (HILIC); Liquid chromatography/mass spectrometry; Deferasirox; Mirtazapine; Human plasma
A new HPLC UV validated method for therapeutic monitoring of deferasirox in thalassaemic patients
Keywords: Deferasirox; HPLC UV; Quantification; Thalassaemic patients
Formation of ultrafine deferasirox particles via rapid expansion of supercritical solution (RESS process) using Taguchi approach
Keywords: Nanoparticles; Iron chelator; Deferasirox; RESS process; SC-CO2; Taguchi
Identification, characterization and quantification of a new impurity in deferasirox active pharmaceutical ingredient by LC–ESI–QT/MS/MS
Keywords: Deferasirox; Impurity; LC–MS/MS; NMR; Validation
Deferasirox exposure induces reactive oxygen species and reduces growth and viability of myelodysplastic hematopoietic progenitors
Keywords: Myelodysplastic syndrome; Hematopoiesis; Progenitors; Iron chelators; Deferasirox; Reactive oxygen species;
Dried blood spot analysis of an iron chelator – Deferasirox and its potential application to therapeutic drug monitoring
Keywords: Deferasirox; Iron chelator; Iron overload; Liquid chromatography–tandem mass spectrometry; Dried blood spot (DBS); FTA-DMPK-C
Management of thalassaemia
Keywords: anaemia; chelation; deferasirox; deferiprone; desferrioxamine; thalassaemia
Positive effects on hematopoiesis in patients with myelodysplastic syndrome receiving deferasirox as oral iron chelation therapy: A brief review
Keywords: Myelodysplastic syndromes; Transfusion dependence; Iron chelation; Deferasirox; Hemopoietic improvement
Clinical management of gastrointestinal disturbances in patients with myelodysplastic syndromes receiving iron chelation treatment with deferasirox
Keywords: Myelodysplastic syndrome; Transfusion; Iron overload; Chelation; Gastrointestinal disturbances; Deferasirox
Spectrofluorimetric determination of buparvaquone in biological fluids, food samples and a pharmaceutical formulation by using terbium-deferasirox probe
Keywords: Buparvaquone; Deferasirox; Fluorescence; Terbium-sensitised luminescence; Biological fluids; Meat; Diary;
Interference of deferasirox with assays for serum iron and serum unsaturated iron binding capacity during iron chelating therapy
Keywords: DFX; deferasirox; sFe; serum iron; UIBC; unsaturated iron binding capacity; DFX-Fe; DFX-iron complex; NTBI; non-transferrin-bound iron; Tf; transferrin; CPBA; competitive protein-binding analysis; Abs; absorbance; Deferasirox; Serum iron; Unsaturated iron
Oral chelators in transfusion-dependent thalassemia major patients may prevent or reverse iron overload complications
Keywords: Thalassemia major; Combined chelation; Deferiprone; Deferasirox; Iron overload complications
Effects of deferasirox on renal function and renal epithelial cell death
Keywords: Deferasirox; Iron chelator; Iron overload; Rats; Renal toxicity; Tubular cell lines
Prospective assessment of effects on iron-overload parameters of deferasirox therapy in patients with myelodysplastic syndromes
Keywords: Iron chelation; Deferasirox; Exjade®; MDS; Pharmacokinetics; MRI
A Prospective Study of Iron Overload Management in Allogeneic Hematopoietic Cell Transplantation Survivors
Keywords: Late Complications; Iron Overload; Phlebotomy; Deferasirox
Deferasirox in iron-overloaded patients with transfusion-dependent myelodysplastic syndromes: Results from the large 1-year EPIC study
Keywords: Myelodysplastic syndromes; Deferasirox; Serum ferritin; Labile plasma iron; Iron chelation therapy